Has AMWELL gone too high too fast?
Like many tech companies, AMWL has grown at an exponential rate while remaining unprofitable. Is there a path to profitability? Sure.
avatar
Mike Sakuraba graduated with double major of English and Economics. Part time writer, part time investor, full time dad. Mike loves writing about technology, sports, and investing.
2020-10-12 10:14

The COVID-19 pandemic has been crippling to many industries but tele-medicine is certainly not one of them. In fact, industry leader Teladoc (NYSE:TDOC) has seen its shares climb over 150% since the beginning of the year, something recent IPO American Well or AMWELL (NYSE:AMWL) is hoping to replicate. The sector is not overcrowded by any means, but tele-medicine has been at the forefront of methods in continuing essential medical services during the global pandemic. The premise is simple: a majority of medical visits need not be in person anymore and while this is something that has been crucial during this pandemic, there certainly is a chance that this continues as a new normal in the future.

Has AMWELL gone too high too fast?

If you have not heard of AMWL, you are not alone. Most investors are familiar with TDOC and how established it is as the leader in this field. After the much publicized announcement of the merger with Livongo Health (NASDAQ:LVGO), TDOC has been on the radar of investors for a better part of this year. Well, AMWL should be on your radar as well if you think that virtual health visits are the way of the future. First, AMWL is extremely popular amongst its users and was recently rated as the number one telemedicine platform in America. Secondly, it is growing and it is growing fast. In the first six months of 2020, AMWL’s revenues grew by nearly 80% year-over-year and with that came a massive rise in monthly visits. Third, it has an incredibly powerful backer: Alphabet, the parent company of Google (NASDAQ:GOOGL) which threw down $100 million in investments. That is some serious cash from the biggest name in the tech space.

Like many tech companies, AMWL has grown at an exponential rate while remaining unprofitable. Is there a path to profitability? Sure. But right now they are stuck in that high growth high spend phase that so many new companies go through. The stock price has jumped nearly 70% since it went public, not even one month ago. We know how popular these new IPO stocks are, but the current valuation is nearly twenty times its trailing annual sales which is a fairly high valuation for a recently public company. But AMWL has some positives too including a fairly squeaky clean balance sheet with very little debt compared to its cash on hand.

Is there space for more than one dominant telemedicine company in the space? Of course. The total addressable market for this sector is anyone who needs to see a physician. Period. AMWL should continue to grow its client base, and rest assured, it is not just investors that are eyeing this opportunity. Recently, rumors of AMWL being acquired by UnitedHealth Group (NYSE:UNH) has raised the eyebrows of more than a few people on Wall Street. Listen, UnitedHealth is the largest healthcare company in the world by revenue, and if companies like this and Alphabet are chomping at the bit to get involved with AMWL, it is often a good sign that investors should too.


Disclaimer: I am long on AMWL. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article. All information should be independently verified and should not be relied upon for purposes of transacting securities or other investments. See terms for more info.

Rate this article

positive
negative
Published On
2020-10-12 10:14

avatar
About the Author
Mike Sakuraba graduated with double major of English and Economics. Part time writer, part time investor, full time dad. Mike loves writing about technology, sports, and investing.


buy-coffee
You've read 1 article in the last year
..thank you for supporting us and for visiting our site. Unlike many other sites, The Dog of Wall Street is available for everyone to read. Our focus is to provide great content for free. Do you like what we are doing? Buy us a cup coffee. It is the fuel that keeps us going..

Is Rivian (RIVN) Stock a Buy Again?
The company continues to bleed money and is losing more than $40,000 per vehicle.
By Mike Sakuraba | 2 weeks ago

2 Stocks to Buy on a Pullback
Here are two stocks I’ll buy if we pull back in March.
By Mike Sakuraba | 2 weeks ago

2 Stocks to Buy for the March Bull Run
Here are 2 I have my eyes on for March.
By Mike Sakuraba | 3 weeks ago

Bitcoin is Hot: 2 Stocks to Buy Now
Here are 2 lesser-known crypto stocks that I think will benefit from Bitcoin’s bull run.
By Mike Sakuraba | 3 weeks ago

2 Stocks to Buy on the Earnings Dip
Here are two stocks that sold off that I have my eye on!
By Mike Sakuraba | 3 weeks ago

2 Stocks I'm Never Buying Again
Never is such a strong word but when it comes to investing, it is easy to never want to buy a stock again.
By Mike Sakuraba | 1 month ago

2 Stocks to Ride the NVIDIA Hype Train
Now that NVIDIA (NASDAQ: NVDA) saved the market again, is it finally time to buy?
By Mike Sakuraba | 1 month ago

Is it Too Late to Buy SMCI Stock?
Is it too late to get into SMCI after this parabolic run?
By Mike Sakuraba | 1 month ago